ReviewGut2020
Albumin in decompensated cirrhosis: new concepts and perspectives.
Review in Gut, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 187 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
187 citing papers in PubMed, 6 syntheses or guidelines pooled it, 338 citations in OpenAlex.
- Albumin for people with liver cirrhosis and bacterial infections.The Cochrane database of systematic reviews · 2026Pooled it
- Effect of human albumin infusion on inflammation, oxidative stress, and prognosis in decompensated cirrhosis: a prospective cohort study with a meta-analysis.BMC gastroenterology · 2026Pooled it
- Prognostic value of prognostic nutritional index in breast cancer patients receiving neoadjuvant therapy: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Neutrophil Percentage-to-Albumin Ratio and Neutrophil-to-Albumin Ratio as novel biomarkers for non-alcoholic fatty liver disease: a systematic review and meta-analysis.Journal of health, population, and nutrition · 2025Pooled it
- Use of human albumin infusion in cirrhotic patients: a systematic review and meta-analysis of randomized controlled trials.Hepatology international · 2022Pooled it
- Novel Anti-inflammatory Treatments in Cirrhosis. A Literature-Based Study.Frontiers in medicine · 2021Pooled it
- A randomized, phase Ib trial of recombinant human serum albumin in cirrhotic patients with ascites.Hepatology international · 2026Trial
- Targeted Albumin Infusions Do Not Improve Systemic Inflammation or Cardiovascular Function in Decompensated Cirrhosis.Clinical and translational gastroenterology · 2022Trial
- Clinical characteristics and prognosis of peritoneal dialysis-associated peritonitis caused by non-fermenting Gram-negative bacteria: a single-center retrospective analysis.Renal failure · 2026Article
- Albumin in the Management of Hepatorenal Syndrome-Acute Kidney Injury: Is There Ever Too Much?Digestive diseases and sciences · 2026Article
- Machine learning phenotypes and heterogeneous albumin effects in cirrhotic AKI: a causal inference study.Internal and emergency medicine · 2026Article
- Albumin-Based Biomarkers and Adverse Outcomes in Coronary Artery Disease: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2026Review
- Enhancing short-term predictions of mortality risk for liver transplant candidates through random survival forests.Scientific reports · 2026Article
- Uncovering immune dysfunction in ACLF: Cellular mechanisms, molecular pathways, and therapeutic frontiers.Journal of hepatology · 2026Review
- Acute-on-Chronic Liver Failure: An Eroded Cliff Hit by a Storm-A Narrative Review.International journal of molecular sciences · 2026Review
- Heparin-Binding Protein and Transplant-Associated Inflammation: Emerging Roles in Infection, Ischemia-Reperfusion Injury, and Allograft Dysfunction.Journal of clinical medicine · 2026Review
- Not Just for Volume Anymore: New Indications for Albumin in Patients with Liver Disease.Digestive diseases and sciences · 2026Article
- Machine learning model for predicting rebleeding risk after endoscopic variceal ligation in esophageal variceal bleeding.Scientific reports · 2026Article
- Article
- Gut dysbiosis and nitric oxide dysregulation in cirrhosis progression: mechanistic insights and pathophysiological implications.Journal of physiology and biochemistry · 2026Review
127 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 9 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pathophysiological background of decompensated cirrhosis is characterised by a systemic proinflammatory and pro-oxidant milieu that plays a major role in the development of multiorgan dysfunction. Such abnormality is mainly due to the systemic spread of bacteria and/or bacterial products from the gut and danger-associated molecular patterns from the diseased liver triggering the release of proinflammatory mediators by activating immune cells. The exacerbation of these processes underlies the development of acute-on-chronic liver failure. A further mechanism promoting multiorgan dysfunction and failure likely consists with a mitochondrial oxidative phosphorylation dysfunction responsible for systemic cellular energy crisis. The systemic proinflammatory and pro-oxidant state of patients with decompensated cirrhosis is also responsible for structural and functional changes in the albumin molecule, which spoil its pleiotropic non-oncotic properties such as antioxidant, scavenging, immune-modulating and endothelium protective functions. The knowledge of these abnormalities provides novel targets for mechanistic treatments. In this respect, the oncotic and non-oncotic properties of albumin make it a potential multitarget agent. This would expand the well-established indications to the use of albumin in decompensated cirrhosis, which mainly aim at improving effective volaemia or preventing its deterioration. Evidence has been recently provided that long-term albumin administration to patients with cirrhosis and ascites improves survival, prevents complications, eases the management of ascites and reduces hospitalisations. However, variant results indicate that further investigations are needed, aiming at confirming the beneficial effects of albumin, clarifying its optimal dosage and administration schedule and identify patients who would benefit most from long-term albumin administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.